Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(2.30)
# 2,664
Out of 5,152 analysts
53
Total ratings
32%
Success rate
4.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Initiates: Overweight | n/a | $4.02 | - | 1 | Dec 18, 2025 | |
| NVAX Novavax | Initiates: Overweight | $18 | $9.89 | +82.00% | 1 | Oct 24, 2025 | |
| ALEC Alector | Downgrades: Neutral | n/a | $2.15 | - | 6 | Oct 22, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Neutral | n/a | $1.42 | - | 5 | Jul 7, 2025 | |
| DRUG Bright Minds Biosciences | Assumes: Overweight | n/a | $79.31 | - | 1 | Jul 2, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $39.65 | +152.21% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $4.13 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $7.58 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.29 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $16.37 | - | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.59 | - | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.81 | - | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $62.03 | - | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $3.28 | +52.44% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $3.31 | +292.75% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $22.52 | -64.48% | 1 | Mar 20, 2023 |
CervoMed
Dec 18, 2025
Initiates: Overweight
Price Target: n/a
Current: $4.02
Upside: -
Novavax
Oct 24, 2025
Initiates: Overweight
Price Target: $18
Current: $9.89
Upside: +82.00%
Alector
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.15
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.42
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $79.31
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $39.65
Upside: +152.21%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.13
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.58
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.29
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.37
Upside: -
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.59
Upside: -
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.81
Upside: -
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $62.03
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $3.28
Upside: +52.44%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $3.31
Upside: +292.75%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $22.52
Upside: -64.48%